Please ensure Javascript is enabled for purposes of website accessibility
Max Macaluso

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent articles

Drawing Biopharma Concepts With A Crayon

Peter Lynch once said, “Never invest in any idea you can’t illustrate with a crayon.” Does that hold true in the highly scientific world of biopharma?


Better Stock Today Challenge: InvenSense vs. Seadrill

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.


Better Stock Today Challenge: InvenSense vs. DistributionNow

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.


Better Stock Today Challenge: InvenSense vs. SodaStream

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.


Better Stock Today Challenge: Apple vs. Annaly Capital

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.

Better Stock Today: InvenSense vs. Johnson & Johnson

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.


Better Stock Today: Vanguard Natural Resources vs. Apple

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.


This Internet of Things Company is Changing Medicine as We Know It

A look at smart-pill pioneer Proteus Digital Health.


The Biggest Threat to Facebook's $19 Billion WhatsApp Buy

Will smaller, more intimate communication networks like WhatsApp start pulling people away from sprawling ones like Facebook?


Will Your Car Have No Steering Wheel in 5 Years? Google Makes Its Self-Driving-Car Move

Will Google be able to get its driverless car, or at least the tech behind it, into the marketplace? Or will companies not want to play ball with the Internet giant?

Why Is Intel Partnering With a Company You've Probably Never Heard Of?

Tech giant Intel has partnered with the relatively unknown Rockchip in an effort to get its chips into inexpensive smartphones and tablets in emerging markets.


Will Google's Nest Disrupt the Smart Home Industry?

Google Inc.'s Nest thermostat and ADT Corp.'s home security systems are but two of the names filling out the already crowded connected-home market.


What's the Future of the Connected TV?

A lot of companies are developing new ways to deliver content to your TV, but will the television watching experience really change in the next few years?


AT&T Inc. Dips Its Toes in the Connected Home

AT&T Inc. is trying to connect consumers' homes with its Digital Life program, but will that in any way affect the company's bottom line?


Understanding Multiple Sclerosis: An Interview With Novartis' Dr. Gordon Francis

Understanding multiple sclerosis and Novartis' drug Gilenya.

An Interview With Harry Kirsch, CFO of Novartis

Novartis CFO Harry Kirsch discusses Novartis' culture and its recent deals with GlaxoSmithKline and Eli Lilly.


CannaVEST Corp.: What Investors Need to Watch

What investors need to watch at CannaVEST


What's Behind the Biotech Crash?

What's the real story behind the rise and fall of the biotech bubble?


Allergan, Inc.: Another Billion-Dollar Buyout Target

Valeant might continue its acquisition streak with the hefty purchase of Allergan.


Biotech Banter: FDA Delay, Clinical Trial News, and Tweet of the Week

The latest from The Motley Fool's biotech show "Biotech Banter."